EQS-Adhoc: Vitruvia Medical AG: Half yearly results as per June 30,2026
|
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Results / Half year/Forecast / Half year Vitruvia Medical AG Half-Year Results as of June 30, 2026 Vitruvia Medical AG posted results in line with expectations in the first half of 2026. The Board of Directors confirms the full-year forecast. Vitruvia Medical AG looks back on a successful first half of 2026 and remains fully on track with its business development. Particularly encouraging is the significant improvement in earnings: With CHF 125,785.97, the company was able to significantly increase its earnings compared to the same period last year (CHF -72,889.88), thereby impressively confirming the positive trajectory it has embarked upon. Based on the company’s business performance in line with plans and the positive trend in the first half of the year, management confirms its positive outlook for the full year 2026 and believes the company remains well-positioned to achieve its targets. LT technologies GmbH & Co. KG, a wholly owned subsidiary of Vitruvia Medical AG, looks back on a strong first half of 2026. The half-year revenue target of €1,300,000 was achieved as planned, putting the company on a stable course to meet its full-year target of €2.6 million.
End of Inside Information
12-Aug-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vitruvia Medical AG |
| Kesselackerstr. 18 | |
| 5611 Anglikon | |
| Switzerland | |
| Phone: | +41 44 915 33 78 |
| E-mail: | kontakt@vitruvia-med.com |
| Internet: | www.vitruvia-med.com |
| ISIN: | CH0461931419 |
| WKN: | A2PDWF |
| Listed: | Regulated Unofficial Market in Munich |
| LEI Code: | 894500BJF754AIR7V312 |
| EQS News ID: | 2381536 |
| End of Announcement | EQS News Service |
|
|
2381536 12-Aug-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 5,60 | 1,97 | 1,42 | 1,75 | 0,00 | 0,21 | 0,00 | |
| EBITDA1,2 | -0,96 | -0,75 | -0,91 | 0,06 | 0,00 | 0,24 | 0,00 | |
| EBITDA-Margin3 | -17,14 | -38,07 | -64,09 | 3,43 | 0,00 | 116,19 | 0,00 | |
| EBIT1,4 | -1,31 | -7,69 | -1,24 | -0,37 | 0,00 | 0,26 | 0,00 | |
| EBIT-Margin5 | -23,39 | -390,36 | -87,32 | -21,14 | 0,00 | 123,81 | 0,00 | |
| Net Profit (Loss)1 | -1,54 | -7,71 | -1,48 | -0,54 | 0,00 | 0,33 | 0,00 | |
| Net-Margin6 | -27,50 | -391,37 | -104,23 | -30,86 | 0,00 | 156,67 | 0,00 | |
| Cashflow1,7 | -0,21 | -0,78 | -0,67 | -0,10 | 0,00 | 0,57 | 0,00 | |
| Earnings per share8 | -0,85 | -4,19 | -0,59 | -0,21 | -0,05 | 0,09 | -0,04 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: blueAudit
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Vitruvia Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2PDWF | CH0461931419 | AG | 5,05 Mio € | 11.05.2021 | 8FVC9778+HW | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -67,00 | 11,11 | -6,03 | -0,54 | 2,27 | 9,69 | 25,62 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.04.2026 | 12.08.2026 | 26.04.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -13,27% | -0,22% | +34,00% | +34,00% | -94,07% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
